Commentary on the results and clinical implications of the PROactive study.
Rizza
Robert
R
American Diabetes Association, 1701 N. Beauregard Street, Alexandria, VA 22311, USA. rkahn@diabetes.org
Henry
Robert
R
Kahn
Richard
R
D000284:Administration, Oral; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D015203:Reproducibility of Results; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D010919:Placebos; D045162:Thiazolidinediones